Regeneron Pharmaceuticals (REGN) seems to be in an optimistic limelight with numerous Wall Street analysts adopting bullish stances towards its stock. The company has recently witnessed a surge in stock by 25%, apparently due to investors' less pessimistic view than previously anticipated. Hedge funds also view REGN as a potentially strong investment among gene-editing stocks. The organization has seen $4.98 million investment by Creative Planning, while Vanguard Group Inc. has acquired more REGN shares.
Notably, FDA approval expansions and pipeline successes could be a game-changer for Regeneron. The stock's PT has been increased to $700 by Wells Fargo & Company, and the company experienced a 4.6% rise in trading following an analyst upgrade. The initiation of new holdings in Regeneron by ABN AMRO Bank N.V., and purchases from Citigroup Inc. and Seizert Capital Partners LLC, enhance the upward trajectory. Despite some selling of shares by various entities and reduction stakes, the overall atmosphere appears very positive with an EC Nod for Libtayo Label Expansion and positive results from late-stage trials and further FDA approvals driving the bullish stance.
Regeneron Pharmaceuticals REGN News Analytics from Thu, 07 Aug 2025 07:00:00 GMT to Sat, 22 Nov 2025 12:57:12 GMT - Rating 8 - Innovation 6 - Information 9 - Rumor -7
